To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women
Status:
Completed
Trial end date:
2021-09-03
Target enrollment:
Participant gender:
Summary
To demonstrate that multiple-dose administration of oral therapeutic and supratherapeutic
doses of aprocitentan do not have a clinically relevant effect on the QT interval.
Phase:
Phase 1
Details
Lead Sponsor:
Idorsia Pharmaceuticals Ltd.
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination